Merck & Co To Break New Ground With Female-Led Organon Unit
Former Chair And CEO Of Humacyte, Carrie Cox To Serve As Chair
The planned spin-off of Merck & Co’s Organon unit, with annual sales of $6.5bn including from biosimilars, is nearing completion, with the originator filing documentation with the SEC and unveiling a progressive female-majority board of directors for the new company.
